Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study

PA Campochiaro, JS Heier, L Feiner, S Gray, N Saroj… - Ophthalmology, 2010 - Elsevier
PA Campochiaro, JS Heier, L Feiner, S Gray, N Saroj, AC Rundle, WY Murahashi, RG Rubio…
Ophthalmology, 2010Elsevier
PURPOSE: To assess efficacy and safety of intraocular injections of 0.3 mg or 0.5 mg
ranibizumab in patients with macular edema following branch retinal vein occlusion (BRVO).
DESIGN: Prospective, randomized, sham injection-controlled, double-masked, multicenter
clinical trial. PARTICIPANTS: A total of 397 patients with macular edema following BRVO.
METHODS: Eligible patients were randomized 1: 1: 1 to receive monthly intraocular
injections of 0.3 mg or 0.5 mg of ranibizumab or sham injections. MAIN OUTCOME …
PURPOSE
To assess efficacy and safety of intraocular injections of 0.3 mg or 0.5 mg ranibizumab in patients with macular edema following branch retinal vein occlusion (BRVO).
DESIGN
Prospective, randomized, sham injection-controlled, double-masked, multicenter clinical trial.
PARTICIPANTS
A total of 397 patients with macular edema following BRVO.
METHODS
Eligible patients were randomized 1:1:1 to receive monthly intraocular injections of 0.3 mg or 0.5 mg of ranibizumab or sham injections.
MAIN OUTCOME MEASURES
The primary efficacy outcome measure was mean change from baseline best-corrected visual acuity (BCVA) letter score at month 6. Secondary outcomes included other parameters of visual function and central foveal thickness (CFT).
RESULTS
Mean (95% confidence interval [CI]) change from baseline BCVA letter score at month 6 was 16.6 (14.7–18.5) and 18.3 (16.0–20.6) in the 0.3 mg and 0.5 mg ranibizumab groups and 7.3 (5.1–9.5) in the sham group (P<0.0001 for each ranibizumab group vs sham). The percentage of patients who gained ≥15 letters in BCVA at month 6 was 55.2% (0.3 mg) and 61.1% (0.5 mg) in the ranibizumab groups and 28.8% in the sham group (P<0.0001 for each ranibizumab group vs sham). At month 6, significantly more ranibizumab-treated patients (0.3 mg, 67.9%; 0.5 mg, 64.9%) had BCVA of ≥20/40 compared with sham patients (41.7%; P<0.0001 for each ranibizumab group vs sham); and CFT had decreased by a mean of 337 μm (0.3 mg) and 345 μm (0.5 mg) in the ranibizumab groups and 158 μm in the sham group (P<0.0001 for each ranibizumab group vs sham). The median percent reduction in excess foveal thickness at month 6 was 97.0% and 97.6% in 0.3 mg and 0.5 mg groups and 27.9% in the sham group. More patients in the sham group (54.5%) received rescue grid laser compared with the 0.3 mg (18.7%) and 0.5 mg (19.8%) ranibizumab groups. The safety profile was consistent with previous phase III ranibizumab trials, and no new safety events were identified in patients with BRVO.
CONCLUSIONS
Intraocular injections of 0.3 mg or 0.5 mg ranibizumab provided rapid, effective treatment for macular edema following BRVO with low rates of ocular and nonocular safety events. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found after the references.
Elsevier